Cellectar Biosciences (CLRB) Competitors

$3.20 +0.26 (+8.84%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$3.10 -0.11 (-3.28%)

As of 08:13 AM Eastern

CLRB vs. MGX, OKUR, XLO, IXHL, and INCR

Should you buy Cellectar Biosciences stock or one of its competitors? MarketBeat compares Cellectar Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectar Biosciences include Metagenomi (MGX), OnKure Therapeutics (OKUR), Xilio Therapeutics (XLO), Incannex Healthcare (IXHL), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry.

How does Cellectar Biosciences compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

16.4% of Cellectar Biosciences shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cellectar Biosciences has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Cellectar Biosciences	N/A	-298.05%	-144.59%

Metagenomi currently has a consensus target price of $9.00, indicating a potential upside of 566.67%. Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 243.75%. Given Metagenomi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Metagenomi is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cellectar Biosciences has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	2.02	-$87.87M	-$2.30	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A

Metagenomi has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 4 more articles in the media than Metagenomi. MarketBeat recorded 14 mentions for Cellectar Biosciences and 10 mentions for Metagenomi. Cellectar Biosciences' average media sentiment score of 0.78 beat Metagenomi's score of -0.16 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Metagenomi beats Cellectar Biosciences on 10 of the 16 factors compared between the two stocks.

How does Cellectar Biosciences compare to OnKure Therapeutics?

Cellectar Biosciences (NASDAQ:CLRB) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Cellectar Biosciences presently has a consensus price target of $11.00, indicating a potential upside of 243.75%. OnKure Therapeutics has a consensus price target of $27.00, indicating a potential upside of 708.38%. Given OnKure Therapeutics' higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cellectar Biosciences had 8 more articles in the media than OnKure Therapeutics. MarketBeat recorded 14 mentions for Cellectar Biosciences and 6 mentions for OnKure Therapeutics. Cellectar Biosciences' average media sentiment score of 0.78 beat OnKure Therapeutics' score of -0.19 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cellectar Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

OnKure Therapeutics' return on equity of -61.02% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-298.05%	-144.59%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Summary

Cellectar Biosciences beats OnKure Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cellectar Biosciences compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Cellectar Biosciences has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.20	-$35.04M	-$5.49	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A

In the previous week, Cellectar Biosciences had 11 more articles in the media than Xilio Therapeutics. MarketBeat recorded 14 mentions for Cellectar Biosciences and 3 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.22 beat Cellectar Biosciences' score of 0.78 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xilio Therapeutics presently has a consensus price target of $28.00, indicating a potential upside of 217.82%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 243.75%. Given Cellectar Biosciences' higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Xilio Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

Cellectar Biosciences has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Cellectar Biosciences	N/A	-298.05%	-144.59%

Summary

Xilio Therapeutics beats Cellectar Biosciences on 9 of the 16 factors compared between the two stocks.

How does Cellectar Biosciences compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Cellectar Biosciences has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	514.32	-$46.88M	-$8.41	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A

In the previous week, Cellectar Biosciences had 7 more articles in the media than Incannex Healthcare. MarketBeat recorded 14 mentions for Cellectar Biosciences and 7 mentions for Incannex Healthcare. Cellectar Biosciences' average media sentiment score of 0.78 beat Incannex Healthcare's score of 0.72 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 243.75%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Incannex Healthcare has a beta of 7.22, meaning that its share price is 622% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

Incannex Healthcare's return on equity of -114.95% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-114.95%	-103.38%
Cellectar Biosciences	N/A	-298.05%	-144.59%

Summary

Cellectar Biosciences beats Incannex Healthcare on 9 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to InterCure?

InterCure (NASDAQ:INCR) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Cellectar Biosciences had 12 more articles in the media than InterCure. MarketBeat recorded 14 mentions for Cellectar Biosciences and 2 mentions for InterCure. Cellectar Biosciences' average media sentiment score of 0.78 beat InterCure's score of 0.43 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Cellectar Biosciences	Positive

InterCure has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.57	-$10.37M	$0.03	27.07
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A

8.3% of InterCure shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

InterCure has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 243.75%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

InterCure's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Cellectar Biosciences	N/A	-298.05%	-144.59%

Summary

InterCure and Cellectar Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.47M	$8.18B	$6.34B	$12.37B
Dividend Yield	N/A	2.53%	2.80%	5.35%
P/E Ratio	-0.34	15.80	20.66	25.63
Price / Sales	N/A	8.38	542.63	76.59
Price / Cash	N/A	16.82	43.26	56.33
Price / Book	1.69	3.63	9.93	6.97
Net Income	-$21.79M	$223.05M	$3.55B	$333.62M
7 Day Performance	3.23%	-1.07%	1.70%	1.09%
1 Month Performance	5.26%	1.86%	0.49%	3.08%
1 Year Performance	-57.96%	2.20%	39.41%	35.68%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	4.4035 of 5 stars	$3.20 +8.8%	$11.00 +243.8%	-55.7%	$12.47M	N/A	N/A	10	News Coverage Earnings Report Gap Down
MGX Metagenomi	2.8448 of 5 stars	$1.34 -0.7%	$9.00 +571.6%	-10.0%	$50.45M	$25.21M	N/A	236	News Coverage Earnings Report Analyst Forecast Gap Down
OKUR OnKure Therapeutics	3.0302 of 5 stars	$3.45 +0.3%	$27.00 +682.8%	+82.5%	$47.15M	N/A	N/A	N/A
XLO Xilio Therapeutics	3.3829 of 5 stars	$7.88 +1.9%	$28.00 +255.3%	-26.0%	$47.12M	$43.77M	N/A	70	Positive News Earnings Report
IXHL Incannex Healthcare	0.4969 of 5 stars	$3.98 -12.1%	N/A	-81.5%	$46.84M	$90K	N/A	3	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. MGX, OKUR, XLO, IXHL, and INCR

How does Cellectar Biosciences compare to Metagenomi?

Summary

How does Cellectar Biosciences compare to OnKure Therapeutics?

Summary

How does Cellectar Biosciences compare to Xilio Therapeutics?

Summary

How does Cellectar Biosciences compare to Incannex Healthcare?

Summary

How does Cellectar Biosciences compare to InterCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. MGX, OKUR, XLO, IXHL, and INCR

How does Cellectar Biosciences compare to Metagenomi?

Do insiders and institutionals believe in MGX or CLRB?

Is MGX or CLRB more profitable?

Do analysts prefer MGX or CLRB?

Which has preferable valuation and earnings, MGX or CLRB?

Which has more volatility and risk, MGX or CLRB?

Does the media favor MGX or CLRB?

Summary

How does Cellectar Biosciences compare to OnKure Therapeutics?

Do analysts prefer CLRB or OKUR?

Does the media refer more to CLRB or OKUR?

Do insiders & institutionals believe in CLRB or OKUR?

Which has more volatility & risk, CLRB or OKUR?

Which has preferable valuation and earnings, CLRB or OKUR?

Is CLRB or OKUR more profitable?

Summary

How does Cellectar Biosciences compare to Xilio Therapeutics?

Which has stronger earnings & valuation, XLO or CLRB?

Does the media prefer XLO or CLRB?

Do insiders and institutionals have more ownership in XLO or CLRB?

Do analysts rate XLO or CLRB?

Which has more risk and volatility, XLO or CLRB?

Is XLO or CLRB more profitable?

Summary

How does Cellectar Biosciences compare to Incannex Healthcare?

Which has stronger valuation and earnings, IXHL or CLRB?

Does the media refer more to IXHL or CLRB?

Do institutionals & insiders hold more shares of IXHL or CLRB?

Do analysts recommend IXHL or CLRB?

Which has more risk and volatility, IXHL or CLRB?

Is IXHL or CLRB more profitable?

Summary

How does Cellectar Biosciences compare to InterCure?

Does the media prefer INCR or CLRB?

Which has higher earnings and valuation, INCR or CLRB?

Do institutionals & insiders hold more shares of INCR or CLRB?

Which has more volatility & risk, INCR or CLRB?

Do analysts recommend INCR or CLRB?

Is INCR or CLRB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools